Can a simple eye treatment stop the need for a corneal transplant?
NCT ID NCT00560651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry collects long-term data from hundreds of people in Germany who have undergone corneal cross linking for keratoconus, a condition where the cornea thins and bulges, causing vision loss. The procedure uses riboflavin (vitamin B2) eye drops and UV light to stiffen the cornea and stop the disease from getting worse. The goal is to see whether this treatment can prevent the need for a corneal transplant over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Corneal cross linking (riboflavin plus UV light)
What this could lead to
If successful, this registry could confirm that corneal cross linking stops keratoconus from worsening and reduces the need for corneal transplants.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Rare complications or limited long-term data may affect conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augenklinik am St. Franziskus Hospital
Münster, 48145, Germany
-
University of Saar
Homburg, 66421, Germany